Route 92 Medical
- Company typePrivate
- Founded2015
- HeadquartersSan Mateo, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Route 92 Medical firmographics
Firmographics- Name
- Route 92 Medical
- Legal name
- Route 92 Medical
- Website
- https://r92m.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Route 92 Medical industry classification
Industry- Product category
- Neurovascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
- akta.pro secondary industry
- Stroke & Vascular Neurology (HLAKAIAG)
Keywords
Where Route 92 Medical is headquartered
LocationHeadquarters
- HQ city
- San Mateo
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Route 92 Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
Revenue model
- Neurovascular Device Sales: Sale of neurovascular thrombectomy products including HiPoint Reperfusion System and FreeClimb catheter systems to hospitals and stroke treatment centers. Revenue generated from one-time device purchases by healthcare facilities performing neurointervention procedures.
- Product Portfolio Expansion: Revenue generated from expanding product portfolio including Tenzing delivery catheters, aspiration systems, and related neurovascular intervention devices.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Route 92 Medical product offering
Product offeringCore offering
Route 92 Medical develops and manufactures catheter-based neurovascular intervention devices for the treatment of acute ischemic stroke. Its portfolio includes the FreeClimb® Catheter Systems (54, 70, 88) powered by proprietary Tenzing® delivery technology, and the FDA-cleared HiPoint® Reperfusion System featuring the Monopoint® approach with a super-bore 0.088-inch aspiration catheter. These products are sold to hospitals, comprehensive stroke centers, and neurointerventional physicians for use in mechanical thrombectomy procedures.
Product overview
Route 92 Medical offers a portfolio of neurovascular intervention products designed for stroke treatment. The core product family includes the FreeClimb Catheter Systems (FreeClimb 54, FreeClimb 70, and FreeClimb 88) powered by Tenzing technology, and the FDA-cleared HiPoint Reperfusion System featuring the Monopoint approach with a super-bore 0.088-inch catheter. These products work together as an integrated procedural solution for acute ischemic stroke treatment through aspiration thrombectomy.
Differentiator
Problem solved
Functional benefit
Brands
- FreeClimb® System: Advanced neurointervention catheter system designed to provide superior performance in tortuous anatomy. Includes FreeClimb 54, FreeClimb 70, and FreeClimb 88 catheter systems powered by Tenzing® technology.
- HiPoint® Reperfusion System
- Tenzing®
- Monopoint Approach
Products and services
- FreeClimb 54 Catheter System
Quantifiable outcome
- 57.5% first-pass effect rate and 68.4% modified first-pass effect rate in clinical study of 193 patients
- +3 more outcomes
Companies that use Route 92 Medical
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Route 92 Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Route 92 Medical partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- St. Michael's Hospital TorontoflagshipFirst commercial cases in Canada performed using Route 92 Medical's HiPoint 88 system. Hospital has established neurovascular infrastructure and reimbursement pathways. Dr. Vitor Mendes Pereira performed initial procedures, marking the company's international expansion milestone.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Route 92 Medical competitors and assessment
Company assessmentDirect peers
- Johnson & Johnson MedTech (Cerenovus): Cerenovus, J&J's neurovascular franchise, offers the Embotrap stent retriever and Cerenovus large-bore catheters. Direct competitor with global commercial infrastructure.
- Stryker (Neurovascular): Stryker's Neurovascular division (acquired via Concentric Medical and later assets) offers stent retrievers (Trevo) and access catheters for stroke thrombectomy. Direct competitor with broader portfolio and larger salesforce.
- Penumbra: Penumbra is the dominant pure-play in aspiration thrombectomy for stroke, offering the RED reperfusion catheter family and Jet engines. Most direct head-to-head competitor to Route 92's HiPoint Monopoint system, serving the same neurointerventionalist customers.
- Medtronic (Neurovascular): Medtronic's Neurovascular business (originating from ev3/Covidien) offers Solitaire stent retriever and React catheter portfolio. Direct competitor across aspiration and stent-retriever thrombectomy.
Emerging players
- Inari Medical: Inari Medical develops mechanical thrombectomy devices primarily for venous thromboembolism, with expanding neurovascular/arterial programs. Comparable emerging player in catheter-based clot removal.
- Viz.ai: Viz.ai provides AI-powered stroke imaging and workflow coordination used by the same neurointerventionalist customer base. Adjacent but enabling to thrombectomy procedures; comparable customer overlap.
- Imperative Care: Imperative Care develops the Zoom stroke reperfusion system including large-bore aspiration catheters. Closely comparable emerging thrombectomy specialist focused on the same acute ischemic stroke indication.
- Rapid Medical: Rapid Medical offers Tigertriever and other adjustable neurovascular devices for stroke intervention. Comparable emerging player in ischemic stroke treatment devices.
- Nico Corporation: Nico Corporation develops specialty neurovascular access and tissue resection devices. Adjacent emerging player serving overlapping neurosurgery/neurointervention specialists.
Broad incumbents
- MicroPort Scientific: MicroPort operates broad neurovascular and cardiovascular device businesses globally, including aspiration and access catheters. Comparable broad incumbent with international reach overlapping Route 92's expansion targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Route 92 Medical social profiles
Digital presenceRoute 92 Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Route 92 Medical leadership team
Management profileNumber of profiles
Profiles4 records
Route 92 Medical funding detail
Funding detailFunding overview
Funding rounds9 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Route 92 Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Route 92 Medical
What does Route 92 Medical do?
Route 92 Medical develops and manufactures catheter-based neurovascular intervention devices for the treatment of acute ischemic stroke. Its portfolio includes the FreeClimb® Catheter Systems (54, 70, 88) powered by proprietary Tenzing® delivery technology, and the FDA-cleared HiPoint® Reperfusion System featuring the Monopoint® approach with a super-bore 0.088-inch aspiration catheter. These products are sold to hospitals, comprehensive stroke centers, and neurointerventional physicians for use in mechanical thrombectomy procedures.
Is Route 92 Medical a public or private company?
Route 92 Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Route 92 Medical founded?
Route 92 Medical was founded in 2015. It employs 11 to 50 people.
Where is Route 92 Medical based?
Route 92 Medical is headquartered in San Mateo, United States, in the North America region.
How does Route 92 Medical make money?
Two revenue lines are on record. Neurovascular Device Sales are the primary driver. The others are product Portfolio Expansion.
Who are Route 92 Medical's main competitors?
Direct peers on record are Johnson & Johnson MedTech (Cerenovus), Stryker (Neurovascular), Penumbra and Medtronic (Neurovascular). Emerging players are Inari Medical, Viz.ai, Imperative Care, Rapid Medical and Nico Corporation. MicroPort Scientific is listed as a broad incumbent.
Does Route 92 Medical have an API?
No public API is recorded for Route 92 Medical.
What industry is Route 92 Medical in?
Route 92 Medical's product category is Neurovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAKAIAG, Stroke & Vascular Neurology. Its NAICS code is 339112 and its SIC code is 3841.